TP53 and acute myeloid leukemia: After adjustment for secondary AML, FLT3/TP53/RUNX1 mutations, and stem cell transplant, the presence of MRD, as assessed by a post-induction persisting NGS-detectable mutation, was independently prognostic of both relapse (HR = 1.85; 95% CI 1.07–3.20; P = 0.027) and death (HR = 2.04; 95% CI 1.17–3.57; P = 0.013) (Table 3).